FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
Suparna Wedam(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Shenghui Tang(United States Food and Drug Administration), Bellinda L. King‐Kallimanis(LUNGevity Foundation), Richard Pazdur(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Marc R. Theoret(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Lola A. Fashoyin‐Aje(Center for Drug Evaluation and Research), Xin Gao(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Erik Bloomquist(Center for Drug Evaluation and Research)
Cited by 92
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k